During the past decade, Chinese University of Hong Kong-Prince of Wales Hospital conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 8 clinical trials were completed, i.e. on average, 44.4% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 4 clinical trials were completed. i.e. 36.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chinese University of Hong Kong-Prince of Wales Hospital" #1 sponsor was "Chinese University of Hong Kong" with 18 trials, followed by "National Cancer Institute (NCI)" with 8 trials sponsored, "Celgene" with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Boston Scientific Corporation" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chinese University of Hong Kong-Prince of Wales Hospital" #1 collaborator was "NRG Oncology" with 3 trials as a collaborator, "National Cancer Institute (NCI)" with 2 trials as a collaborator and "UCB Pharma" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Chinese University of Hong Kong-Prince of Wales Hospital" are "Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma" (3 trials), "Nasopharyngeal Nonkeratinizing Carcinoma" (2 trials), "Pain" (2 trials), "Recurrent Nasopharyngeal Undifferentiated Carcinoma" (2 trials) and "Adult Nasal Type Extranodal NK/T-Cell Lymphoma" (1 trials). Many other conditions were trialed in "Chinese University of Hong Kong-Prince of Wales Hospital" in a lesser frequency.

Most popular intervention types in "Chinese University of Hong Kong-Prince of Wales Hospital" are "Drug" (18 trials), "Other" (9 trials), "Procedure" (8 trials), "Biological" (5 trials) and "Device" (3 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (6 trials), "Cisplatin" (3 trials), "Cetuximab" (2 trials), "Electroacupuncture" (2 trials) and "Gemcitabine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Chinese University of Hong Kong-Prince of Wales Hospital" are 33 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Chinese University of Hong Kong-Prince of Wales Hospital". undefined are not yet recruiting, 10 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Chinese University of Hong Kong-Prince of Wales Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Chinese University of Hong Kong-Prince of Wales Hospital, 2 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 8 trials that are defined as “Not Applicable".